TESARO Inc (TSRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
85
About the Report
About the Report
Summary
TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The company's product portfolio includes ZEJULA (niraparib), to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and VARUBI (rolapitant) for the prevention of chemotherapy induced nausea and vomiting (CINV). TESARO sells its products directly to hospitals and clinics, and to a limited number of specialty distributors and pharmacy providers in the US and to certain wholesale distributors in Europe. TESARO is headquartered in Waltham, Massachusetts, the US.
TESARO Inc (TSRO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
TESARO Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10
TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
TESARO Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Tesaro Enters into Collaboration Agreement with Genentech 13
Tesaro and Medison Pharma Enter into Distribution Agreement 14
Tesaro Enters into Partnership with Genentech 15
OncoQuest Enters into Agreement with Tesaro 16
Evotec and Tesaro Enter into Agreement 17
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18
Licensing Agreements 19
TESARO Enters into Research and Licensing Agreement with TeneoBio 19
Millennium Pharma Enters into Licensing Agreement with Tesaro 20
Zai Lab Enters into Licensing Agreement with Tesaro 21
Janssen Biotech Enters into Licensing agreement with Tesaro 22
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24
Tesaro Amends Licensing Agreement With AnaptysBio 25
Tesaro Enters into Licensing Agreement with AstraZeneca 26
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27
Equity Offering 28
Tesaro Raises USD236.3 Million in Public Offering of Shares 28
Tesaro Raises USD433.2 Million in Public Offering of Shares 30
Tesaro Raises USD50 Million in Private Placement of Shares 32
Tesaro Raises up to USD155 Million in Private Placement of Shares 33
Tesaro Raises USD191.5 Million in Public Offering of Shares 35
Tesaro Completes Public Offering Of Shares For USD 100.8 Million 37
Tesaro Completes Public Offering Of Common Stock For USD 98 Million 38
Tesaro Announces Partial Exercise Of Underwriter's Option For IPO For USD 87 Million 39
Debt Offering 41
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41
Asset Transactions 43
TerSera Therapeutics to Acquire North American Rights to Varubi from TESARO 43
Acquisition 44
Tesaro May Sell Itself 44
TESARO Inc-Key Competitors 45
TESARO Inc-Key Employees 46
TESARO Inc-Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Financial Announcements 48
Nov 01, 2018: TESARO announces third-quarter 2018 operating results 48
Aug 02, 2018: TESARO announces second-quarter 2018 operating results 51
May 03, 2018: TESARO Announces First-Quarter 2018 Operating Results 53
Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results 54
Nov 07, 2017: TESARO Announces Third-Quarter 2017 Operating Results 58
Aug 08, 2017: TESARO Announces Second-Quarter 2017 Operating Results 60
May 09, 2017: TESARO Announces First-Quarter 2017 Operating Results 62
Feb 28, 2017: TESARO Announces Fourth-Quarter 2016 Operating Results 64
Government and Public Interest 66
May 08, 2018: Psychological Effects of Ovarian Cancer Often Overlooked But Can Have a Significant Impact on Patients 66
Product News 68
10/25/2017: TESARO Announces U.S. FDA Approval of VARUBI IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy 68
02/27/2017: TESARO Receives Positive CHMP Opinion for VARUBY 70
02/23/2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant) 71
01/12/2018: TESARO Announces Updates to the U.S. Prescribing Information for VARUBI (rolapitant) Injectable Emulsion 72
Product Approvals 73
Sep 11, 2017: NHS Scotland Recommends Tesaro's Varuby (Rolapitant) For Delayed Nausea And Vomiting In Adults Undergoing Highly Emetogenic Chemotherapy 73
Apr 26, 2017: TESARO Announces Approval of VARUBY (Oral Rolapitant Tablets) by European Commission 74
Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA 76
Clinical Trials 77
Nov 28, 2017: TESARO Announces Availability of VARUBI (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States 77
Sep 11, 2017: TESARO Summarizes TSR-042 Data Presented at 2017 ESMO Annual Meeting 79
Aug 25, 2017: TESARO Presents Poster on TSR-042 at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting 80
Apr 27, 2017: TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 81
Other Significant Developments 82
Jun 03, 2017: TESARO Provides Business and Pipeline Update at ASCO Investor Briefing 82
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85
List of Figure
List of Figures
TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
TESARO Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TESARO Inc, Deals By Therapy Area, 2012 to YTD 2018 9
TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10
TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Tesaro Enters into Collaboration Agreement with Genentech 13
Tesaro and Medison Pharma Enter into Distribution Agreement 14
Tesaro Enters into Partnership with Genentech 15
OncoQuest Enters into Agreement with Tesaro 16
Evotec and Tesaro Enter into Agreement 17
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18
TESARO Enters into Research and Licensing Agreement with TeneoBio 19
Millennium Pharma Enters into Licensing Agreement with Tesaro 20
Zai Lab Enters into Licensing Agreement with Tesaro 21
Janssen Biotech Enters into Licensing agreement with Tesaro 22
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24
Tesaro Amends Licensing Agreement With AnaptysBio 25
Tesaro Enters into Licensing Agreement with AstraZeneca 26
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27
Tesaro Raises USD236.3 Million in Public Offering of Shares 28
Tesaro Raises USD433.2 Million in Public Offering of Shares 30
Tesaro Raises USD50 Million in Private Placement of Shares 32
Tesaro Raises up to USD155 Million in Private Placement of Shares 33
Tesaro Raises USD191.5 Million in Public Offering of Shares 35
Tesaro Completes Public Offering Of Shares For USD 100.8 Million 37
Tesaro Completes Public Offering Of Common Stock For USD 98 Million 38
Tesaro Announces Partial Exercise Of Underwriter's Option For IPO For USD 87 Million 39
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41
TerSera Therapeutics to Acquire North American Rights to Varubi from TESARO 43
Tesaro May Sell Itself 44
TESARO Inc, Key Competitors 45
TESARO Inc, Key Employees 46
TESARO Inc, Subsidiaries 47
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.